Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | SOS1 | Q07889 | 2/20 | 0.43 |
| ▸ | MAOA | P21397 | 2/20 | 0.41 |
| ▸ | MAOB | P27338 | 2/20 | 0.41 |
| ▸ | AR | P10275 | 1/20 | 0.39 |
| ▸ | ERN1 | O75460 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | CASP6 | P55212 | 1/20 | 0.37 |
| ▸ | BCHE | P06276 | 3/20 | 0.37 |
| ▸ | ACHE | P22303 | 3/20 | 0.37 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5175967 | 0.88 | SOS1 (0.44) | TDP1SOS1MAOAMAOBAR | |
| SCHEMBL6142714 | 0.86 | ALDH1A1 (0.42) | SOS1ALDH1A1 | |
| SCHEMBL31556421 | 0.85 | HSP90AA1 (0.46) | TDP1SOS1ALDH1A1 | |
| SCHEMBL23709919 | 0.84 | LMNA (0.50) | TDP1SOS1MAOAMAOBERN1 | |
| SCHEMBL24181300 | 0.83 | TEAD4 (0.41) | TDP1SOS1ARERN1SMN1; SMN2 | |
| SCHEMBL756641 | 0.83 | ALDH1A1 (0.51) | ERN1ALDH1A1 | |
| SCHEMBL15809138 | 0.82 | TDP1 (0.62) | TDP1SOS1MAOAMAOBERN1 | |
| SCHEMBL26980167 | 0.81 | SOS1 (0.38) | SOS1ERN1SMN1; SMN2HSD17B10ALDH1A1 | |
| SCHEMBL12952645 | 0.80 | EPHX2 (0.38) | SOS1 | |
| SCHEMBL31556432 | 0.80 | EPHX2 (0.38) | SOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220185815-A1 | PYRROLOPYRAZOLE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-06-16 | — | — | US | disclosed |
| CN-113543852-A | Pyrrolopyrazole derivatives | 第一三共株式会社 | 2021-10-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220185815-A1 | PYRROLOPYRAZOLE DERIVATIVE | PTDSS1, PTDSS2, SMPD1 | TDP1 1723/4885SOS1 1058/4885MAOA 4824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.